Bone Biologics Corp(BBLG) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.61 | Insider Own | 0.02% | Shs Outstand | 2.8M | Perf Week | 4.64% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 45.53% | Insider Trans | - | Shs Float | 2.8M | Perf Month | -19.89% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | -0.19 | Inst Own | 0.95% | Short Float | 1.79% | Perf Quarter | -62.09% |
| Income | -0.00B | P/S | - | EPS this Y | 53.58% | Inst Trans | 5.13% | Short Ratio | 0.13 | Perf Half Y | -69.96% |
| Sales | 0.00B | P/B | 0.19 | EPS next 5Y | - | ROA | -50.55% | Short Interest | 0.05M | Perf YTD | -72.03% |
| Book/sh | 2.17 | P/C | 0.28 | EPS past 3/5Y | 75.82% 68.85% | ROE | -54.96% | 52W High | -83.74% ($2.49) | Perf Year | -81.56% |
| Cash/sh | 1.46 | P/FCF | - | Sales past 3/5Y | - | ROIC | -73.66% | 52W Low | 7.09% ($0.38) | Perf 3Y | -98.59% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 92.16% | Gross Margin | - | Volatility(W/M) | 7.73% 6.75% | Perf 5Y | -99.99% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.04 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 8.67 | EPS Q/Q | 67.57% | Profit Margin | - | RSI (14) | 31.08 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.67 | Sales Q/Q | - | SMA20 | -10.58% ($0.46) | Beta | 0.9 | Target Price | $12.2 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/09/02 | SMA50 | -22.81% ($0.53) | Rel Volume | 0.07 | Prev Close | $0.42 |
| Employees | 2 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -63.06% ($1.11) | Avg Volume(3M) | 0.38M | Price | $0.41 |
| IPO | 2016/3/31 | Option/Short | No/Yes | Trades | 96 | Volume | 25,139 | Change | -3.43% |
🦴 A biotech company developing orthobiologic bone graft products for spinal fusion, trauma, and osteoporosis treatment. It holds a bone regeneration technology platform based on the NELL-1 protein.
Over the past 1 year, on the lower side
84% below its 1-year high.
Traded less than usual. That is 7% of its average volume.
BBLG has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +53.6% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Positive and negative signals are mixed
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.9%.
Tap to view numbers
It ranks #589 of 594 in the industry
Based on market cap of $1M.
ARTL#586 Artelo Biosciences Inc $1M PER - 
MLEC#587 Moolec Science SA $1M PER - 
LABT#588 Lakewood-Amedex Biotherapeutics Inc $1M PER - BBLG#589 Bone Biologics Corp $1M PER - 
CRIS#590 Curis Inc $1M PER - 
FAQ
What kind of company is BBLG?
BBLG belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BBLG?
The market cap of BBLG is approximately $1M, ranking 5,859 within its sector.
What is the 52-week high and low for BBLG?
BBLG has recorded a 52-week high of $2.49 and a low of $0.38.
